Zydus Cadila receives tentative approval from USFDA for Pemetrexed for Injection

Zydus Cadila has received tentative approval from the USFDA to market Pemetrexed for Injection in the strengths of 100mg/vial, 500 mg/vial, and 1000 mg/vial, single-dose vials (US RLD: Alimta). Pemetrexed is used to treat certain types of cancers such as lung cancer, mesothelioma. It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells.

The drug will be manufactured at the formulation manufacturing facility at Zydus Hospira, Ahmedabad. The group now has 319 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.617.7 as compared to the previous close of Rs. 624.35. The total number of shares traded during the day was 159046 in over 5403 trades.

The stock hit an intraday high of Rs. 624.25 and intraday low of 615.05. The net turnover during the day was Rs. 98456448.

Source : Equity Bulls

Keywords